Central to this research initiative is the exploration of extracellular matrix proteins, a class of biomolecules that form the structural and functional scaffolding outside cells. Of particular interest within this complex microenvironment is fibulin-3, an extracellular matrix glycoprotein implicated in maintaining the integrity and homeostasis of retinal tissues. Mutations and alterations in the fibroblast-derived fibulin-3 have been identified as key contributors to the pathogenesis of various blinding disorders, positioning this protein at the forefront of retinal disease research. Understanding fibulin-3’s biological role and its dysregulation promises to unlock novel therapeutic avenues for preventing vision loss.

Professor John Hulleman, PhD, an esteemed ophthalmology and visual neurosciences researcher at the University of Minnesota Medical School, emphasizes the significance of this endeavor. He remarks that the project not only intensifies the focus on fibulin-3’s molecular dynamics but also strives to develop sophisticated tools to dissect its functional interactions within the retinal extracellular matrix. This approach underscores a shift towards targeting the extracellular matrix environment itself, rather than solely focusing on intra-cellular pathways, thus broadening the horizon for innovative treatment modalities.

Age-related macular degeneration, a leading cause of irreversible vision loss among the elderly, is characterized by progressive degeneration of the macula, the central region of the retina responsible for sharp, central vision. Current therapies, while somewhat effective in managing symptoms, often fail to halt or reverse the underlying pathology. The research spearheaded by the University of Minnesota seeks to transcend these limitations by identifying molecular targets within the extracellular matrix that mediate AMD progression, which could lead to breakthrough treatments with enhanced efficacy.

Alongside AMD, the project addresses Doyne honeycomb retinal dystrophy, a rare congenital disorder exhibiting clinical and pathological overlap with AMD. DHRD/ML is marked by the deposition of abnormal extracellular materials within the retina, leading to impaired photoreceptor function and progressive vision deterioration. Dissecting the mechanistic pathways governing extracellular matrix remodeling in DHRD/ML through the lens of fibulin-3 aberrations provides a unique opportunity to develop targeted interventions that can ameliorate or even prevent the disease’s progression.

The research team will undertake a comprehensive pharmacological screening of existing FDA-approved drugs with the objective of repurposing them to mitigate AMD symptoms. This strategy leverages the pharmacokinetic profiles and safety data of known medications, potentially accelerating the timeline for clinical application. Simultaneously, the investigation will delve into the biological mechanisms regulating the synthesis, assembly, and degradation of retinal extracellular matrix proteins, aiming to delineate the homeostatic balances integral to healthy retinal function.

A significant aspect of the study involves characterizing the cellular pathways that control fibulin-3 expression and turnover, which are pivotal in maintaining extracellular matrix stability. Disruptions in these processes can lead to pathological accumulation or deficiency of critical matrix components, contributing to disease pathology. By elucidating these control mechanisms, the team aims to identify molecular checkpoints amenable to therapeutic modulation.

To facilitate these objectives, the researchers employ an array of sophisticated methodologies, including advanced imaging techniques, proteomic analyses, and in vitro cellular models that recapitulate retinal architecture and extracellular matrix interactions. These technologies enable high-resolution tracking of protein dynamics and intercellular communication in both normal and diseased states, generating critical insights into retinal degeneration.

Moreover, the initiative recognizes the intricate interplay between genetic predispositions and environmental factors in retinal disease etiology. Investigations into how fibulin-3 mutations influence extracellular matrix composition under various physiological conditions will enhance understanding of disease variability and patient-specific responses. This knowledge is essential for the future development of personalized medicine approaches tailored to individual molecular profiles.

The translational potential of this project is fortified by its dual approach, combining fundamental scientific inquiry with a pragmatic search for viable therapeutics. The anticipated outcomes include the generation of novel diagnostic biomarkers and the formulation of innovative treatment protocols that could significantly improve patients’ quality of life. This work exemplifies the integration of biomedical research with clinical imperatives, embodying a future where vision preservation is attainable.

Currently active under grant number 2R01EY027785-07A1, this endeavor not only epitomizes the University of Minnesota Medical School’s commitment to scientific excellence but also signifies a beacon of hope for millions affected by retinal degenerative diseases worldwide. Through rigorous investigation and cutting-edge technology, the research team is poised to reshape the landscape of vision science and ocular therapeutics.

As the study progresses, continuous updates and detailed findings are expected to stimulate further scientific inquiry and collaborative efforts across the biomedical community. The potential to bridge gaps between molecular understanding and clinical innovation positions this project as a landmark in the quest to combat retinal blindness.

Subject of Research: Molecular mechanisms and therapeutic development targeting extracellular matrix protein fibulin-3 in retinal diseases including age-related macular degeneration and Doyne honeycomb retinal dystrophy.

Article Title: University of Minnesota Researchers Secure $2.2M NIH Grant to Target Fibulin-3 in Retinal Disorders

News Publication Date: June 16, 2026

Web References:
https://med.umn.edu/bio/john-hulleman-phd
https://med.umn.edu/

Keywords:
Retinal diseases, Age-related macular degeneration, Doyne honeycomb retinal dystrophy, Malattia Leventinese, Fibulin-3, Extracellular matrix, Ophthalmology, Visual neuroscience, Drug repurposing, Molecular biology, Retinopathy, Therapeutic development

Diabetic retinopathy remains one of the leading causes of vision loss among adults around the globe, presenting a significant burden on healthcare systems. While blood sugar management is crucial, the underlying mechanisms that drive this complication have remained obscure until recent advances in genomics and proteomics illuminated the role of various genetic components like HLA-A. The research team’s findings suggest that HLA-A is not merely a passive player in the immune landscape but actively contributes to the pathological processes seen in diabetic retinopathy.

The concept of multi-omics integration employed in the study represents a paradigm shift in how researchers can approach complex diseases. By correlating vast datasets that include genomics, transcriptomics, proteomics, and metabolomics, the team has crafted a more holistic view of diabetic retinopathy’s etiology. This technique enables researchers to see beyond individual biomarkers to understand how various components interact within biological systems to exacerbate or mitigate disease processes.

Resveratrol, a natural compound found in grapes, berries, and nuts, has gained attention for its health benefits, including anti-inflammatory and antioxidant properties. Given the study’s findings, resveratrol could serve as an immunomodulator that not only reduces inflammation but also possibly stabilizes the immune response in diabetic retinopathy. This intriguing possibility marks a significant step forward, as current treatments primarily focus on managing symptoms rather than targeting the underlying molecular pathways involved in the disease process.

The multi-omics approach utilized in the study revealed a differential expression of immune-related genes, some of which were directly associated with HLA-A. This correlation points to the critical role of the immune system in the progression of diabetic retinopathy. By modulating immune responses, researchers speculate that therapies leveraging compounds like resveratrol could break the cycle of inflammation and cellular stress that worsen eye health in diabetic patients.

Moreover, this research sheds light on an often-overlooked aspect of diabetes care: the role of lifestyle and dietary interventions. As resveratrol is a compound found in many common foods, its integration into dietary recommendations for diabetic patients could become a pivotal step in the management of not only their blood sugar levels but also their ocular health. The potential for such non-pharmacological interventions is particularly appealing in an era where patients are increasingly seeking holistic and complementary approaches to disease management.

The study’s authors emphasize the importance of collaborative research efforts to validate their findings further. They advocate for cross-disciplinary initiatives that combine genetics, nutrition, and immunology to deepen understanding and improve treatment outcomes. Such partnerships could foster innovation, potentially leading to new therapeutic agents derived from natural compounds like resveratrol.

This revelation about HLA-A and its involvement in diabetic retinopathy challenges conventional wisdom and underscores the complexity of autoimmune phenomena in chronic diseases. While it opens the door to new therapeutic angles, it also calls for further research to explore the mechanisms by which HLA-A influences disease severity and progression. Scientists may need to delve deeper into how the immune system in isolation can act to either protect or harm retinal health, depending on how it is modulated.

The excitement around this research is palpable not only in the realm of ocular health but also in the broader field of chronic disease management. Understanding that immunomodulatory therapies could be a future standard of care invites a refreshing perspective on diabetic complications. Collaboration among professionals from various sectors can hasten the translation of these findings into clinical practice, ultimately improving quality of life for patients living with diabetes and its complications.

Looking forward, the researchers stress the need for more extensive clinical trials to assess the efficacy and safety of resveratrol as a therapeutic agent in patients with diabetic retinopathy. Ensuring that this natural compound can be safely integrated into treatment regimens will be key. Additionally, the exploration of genetically individualized medicine, where treatments are tailored based on a patient’s specific genetic makeup, could complement these strategies for more efficacious outcomes.

As the world moves towards an era of precision medicine, this study stands as a testament to the potential of integrating diverse scientific disciplines, harnessing the power of nature through compounds like resveratrol, and enriching our understanding of complex diseases such as diabetic retinopathy. This research serves as a clarion call for continued exploration into the intersection of immune responses, nutrition, and chronic disease management.

In summary, the ongoing exploration of HLA-A and its relationship to diabetic retinopathy has the potential to redefine our approach to treating this prevalent disease. By shedding light on the intricate biological networks at play and suggesting a feasible, integrative dietary intervention, researchers provide a hopeful outlook for those affected by the burdens of diabetes. The implications of this study extend far beyond the confines of academia, aiming to directly influence clinical practices and improve patient outcomes in the fight against diabetic complications.

In closing, it is evident that the research conducted by Lin et al. propels diabetic retinopathy into the spotlight of promising new treatments and therapeutic strategies. As the science evolves, one can hope that these findings catalyze a new wave of interest and investment in developing effective strategies to combat not only diabetic retinopathy but also other diabetes-related complications.

Subject of Research: The role of HLA-A in diabetic retinopathy pathogenesis and the therapeutic potential of resveratrol via immunomodulation.

Article Title: HLA-A drives diabetic retinopathy pathogenesis: multi-omics integration reveals resveratrol’s therapeutic potential via immunomodulation.

Article References: Lin, J., Liang, F., Liu, Y. et al. HLA-A drives diabetic retinopathy pathogenesis: multi-omics integration reveals resveratrol’s therapeutic potential via immunomodulation. J Transl Med 23, 1311 (2025). https://doi.org/10.1186/s12967-025-07117-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07117-7

Keywords: Diabetic retinopathy, HLA-A, resveratrol, immunomodulation, multi-omics integration, genetic research, therapeutic potential, chronic disease, ocular health.

The mechanism of action described by Lou involves the utilization of AAV vectors, which are recognized for their ability to deliver genetic material into host cells efficiently. By employing these vectors to increase the expression of STC-1, a secreted glycoprotein with known neuroprotective properties, researchers are embarking on a novel therapeutic pathway. The increased production of STC-1 is theorized to dampen neuroinflammatory responses within the retina, a key contributor to the progression of degenerative retinopathy. This suppression of inflammation could be pivotal in preserving both retinal structure and function, potentially reversing or halting the damage caused by the disease.

To understand the significance of this research, it is essential to delve into the complexities of neuroinflammation and its role in ocular health. Degenerative retinopathy is often characterized by the activation of microglia and Müller glial cells, leading to a cascade of inflammatory signals that further exacerbate neuronal damage. By harnessing the power of STC-1, the goal is to inhibit these inflammatory pathways, thereby creating an environment conducive to retinal cell survival. The implications of this approach extend beyond mere visual preservation; they suggest a comprehensive strategy to foster retinal repair and regeneration.

Lou’s correspondence does not merely present an isolated finding; rather, it ignites a broader conversation about the potential applications of gene therapy in treating various ocular diseases. The concept of using AAV as a delivery mechanism is not new, but its application in the context of STC-1 expression emphasizes a targeted approach that could set a precedent for future studies. This technique highlights the versatility of AAV vectors in dealing with complex conditions that, until now, have posed insurmountable challenges in therapeutic intervention.

Furthermore, the findings allude to a fascinating synergy between genetic engineering and ocular pharmacology. As the scientific community zeroes in on the molecular underpinnings of diseases, integrating gene delivery systems with therapeutic proteins like STC-1 may redefine treatment paradigms. This paradigm shift is not solely theoretical; preliminary results provided by Lou suggest tangible clinical benefits, which, if substantiated in future studies, could lead to a new class of therapies specifically designed for degenerative retinal conditions.

It is also important to consider the safety and efficacy of such treatment modalities. The journey from the laboratory bench to the clinic requires extensive validation to ensure that the benefits of AAV-mediated STC-1 expression outweigh any potential risks. Previous studies involving AAV have demonstrated a favorable safety profile, yet the addition of neuroprotective factors amplifies the urgency for clinical trials to rigorously assess this innovative approach. The potential for STC-1 to modulate the retinal healing process invites further inquiry into dosing parameters, delivery methods, and long-term patient outcomes.

To contextualize this research within the ongoing discourse on vision restoration, it is essential to reference the larger landscape of retinal therapeutics. With various existing treatments such as anti-VEGF therapies and retinal implants, there is a persistent demand for innovative solutions. Lou’s research brings to light a possibility that traditional modalities alone may not sufficiently address the neurodegenerative aspects accompanying retinopathy. The ability to target inflammation while supporting cellular integrity presents an enticing avenue for exploration.

As excitement builds among researchers, clinicians, and patients alike, the findings brought forth by Lou represent a significant step towards understanding how to reclaim vision lost to degenerative diseases. The integration of gene therapy using AAV vectors alongside neuroprotective agents exemplifies a proactive approach to combating retinal degeneration. It may not only lead to improved visual outcomes but also inspire a new wave of research in regenerative medicine that targets multifaceted aspects of ocular diseases.

Ultimately, the implications of Lou’s letter extend beyond the immediate findings. It serves as a clarion call for the need to expand gene therapy applications across a multitude of conditions. By synergizing genetic interventions with established therapeutic targets, the research community can open doors to previously unimaginable treatments that could alter the trajectory of degenerative eye diseases.

The future of ocular medicine looks promising as researchers work diligently to transform these insights into clinical realities. With dedicated efforts and enhanced collaboration across disciplines, the dream of halting vision loss due to degenerative retinopathies may soon materialize, offering hope and improved quality of life for countless individuals affected by these relentless conditions.

As this field of research progresses, it will be crucial to maintain a balance between innovation and caution. While the potential benefits of AAV-mediated STC-1 expression in retinopathy are enormous, comprehensive studies will be imperative in establishing safety and efficacy benchmarks. The scientific community’s commitment to rigorously testing these hypotheses will ultimately determine whether we can translate this research into effective clinical therapies.

In summary, this letter by J. Lou is a crucial contribution to ongoing research related to degenerative retinopathy. It not only opens up a new avenue for drug development but also sets the stage for future studies aimed at further dissecting the roles of neuroinflammatory mediators in retinal health and disease. The potential of AAV-mediated gene therapies represents a paradigm shift that could redefine treatment strategies for ocular degenerative conditions, making this an exciting era for ophthalmology.

Subject of Research: Gene therapy targeting neuroinflammation in degenerative retinopathy.

Article Title: Letter to editor: AAV-mediated STC-1 expression mitigates neuroinflammation and preserves visual function in degenerative retinopathy.

Article References:

Lou, J. Letter to editor: AAV-mediated STC-1 expression mitigates neuroinflammation and preserves visual function in degenerative retinopathy. J Transl Med 23, 1275 (2025). https://doi.org/10.1186/s12967-025-07125-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07125-7

Keywords: Gene therapy, AAV, STC-1, neuroinflammation, degenerative retinopathy, visual preservation, ocular medicine, therapeutic strategies, regenerative medicine.

Glaucoma, a group of eye conditions often linked to elevated intraocular pressure, leads to optic nerve damage and irreversible blindness. Central to the pathology is the impaired outflow of aqueous humor, the fluid responsible for maintaining eye shape and nutrient transport. The trabecular meshwork, a spongy tissue facilitating this drainage, frequently malfunctions during disease progression. Despite current pharmacological and surgical interventions, many patients experience insufficient pressure control, necessitating innovative approaches that target underlying cellular dysfunction.

The research team explored the therapeutic potential of patient-derived iPSCs differentiated into ITGA6-positive cells, a subpopulation believed to share critical properties with trabecular meshwork cells. ITGA6, an integrin implicated in cell adhesion and signaling, serves as a biomarker for selecting regenerative cells capable of integrating into the damaged tissue milieu. By transplanting these cells into glaucoma models, the investigators observed notable restoration of aqueous humor dynamics, suggesting functional incorporation and beneficial modification of the outflow pathways.

Methodologically, the study meticulously characterized the molecular and phenotypic identity of ITGA6-positive cells prior to transplantation. High-resolution imaging and gene expression profiling validated their resemblance to native trabecular meshwork cells, including the expression of extracellular matrix components and mechanotransduction elements crucial for pressure regulation. This rigorous characterization underpins the mechanistic understanding of how these cells interact with host tissues to promote physiological fluid drainage.

In vivo transplantation experiments, using sophisticated glaucoma animal models, provided compelling evidence of therapeutic efficacy. Subjects receiving iPSC-derived ITGA6-positive cells showed marked improvements in intraocular pressure metrics and maintenance of retinal ganglion cell integrity, key indicators of preserved visual function. Importantly, the intervention demonstrated a favorable safety profile, with no aberrant cell proliferation or immune rejection, highlighting its translational promise.

The implications of this study extend beyond cellular replacement therapy, offering insights into the microenvironmental cues and signaling pathways that govern trabecular meshwork homeostasis. The integrin-mediated interactions facilitated by ITGA6-positive cells may modulate extracellular matrix remodeling and endothelial function, processes that are crucial for sustaining unobstructed aqueous humor outflow. Understanding these mechanisms could catalyze the development of adjunctive treatments that enhance cell therapy outcomes.

Additionally, the use of iPSCs circumvents many ethical and immunological challenges associated with other stem cell sources. Patient-specific cells can be generated, reducing the risk of immune rejection and enabling personalized regenerative interventions. This approach aligns with the burgeoning paradigm of precision medicine, where therapeutic strategies are tailored to individual cellular and genetic profiles.

The study also addresses a significant barrier in glaucoma management: the lack of regenerative options targeted at the trabecular meshwork. While neuroprotective strategies and pressure-lowering drugs predominate current clinical practice, regenerating or replacing defective outflow tissue represents a paradigm shift. Such cellular therapies could complement existing treatments, offering durable solutions that mitigate disease progression at its source.

Challenges remain, particularly regarding the optimization of cell delivery methods and long-term integration within the complex ocular environment. Future research will need to refine transplantation protocols, ensure cell survival and functionality over extended periods, and evaluate efficacy across diverse patient populations and glaucoma subtypes. Nonetheless, this investigation lays vital groundwork for subsequent translational endeavors.

Moreover, the research emphasizes the utility of advanced stem cell technologies in ophthalmology, an emerging frontier that has seen successes in treating retinal degenerative diseases but has remained relatively underexplored for anterior segment disorders. By bridging this gap, the study opens new avenues for tackling other conditions characterized by aberrant tissue function or loss.

In the broader context of regenerative medicine, the demonstration that iPSC-derived ITGA6-positive cells can restore physiological function in a complex tissue system underscores the transformative potential of cell therapy. It exemplifies how combining stem cell biology with precise molecular targeting can yield restorative outcomes in tissues historically resistant to repair.

This research also invites considerations regarding regulatory pathways for approving cellular therapies, highlighting the importance of robust preclinical validation and the establishment of standardized manufacturing processes. Ensuring reproducibility and safety will be essential for transitioning from experimental models to widespread clinical use.

Overall, the discovery of ITGA6-positive cell transplantation as a means to restore aqueous humor outflow marks a milestone in glaucoma research. It invigorates hope for developing treatments that not only halt disease progression but actively reverse structural dysfunction within the eye, promising a future where vision preservation is substantially enhanced for at-risk populations.

Scientists and clinicians alike are eagerly anticipating developments stemming from these findings, which may soon translate into novel clinical protocols. As the field advances, interdisciplinary collaborations integrating stem cell biology, ophthalmology, and bioengineering will be pivotal in refining these therapies and ensuring their success.

The report, published in Nature Communications, has already garnered significant attention for its innovative approach and potential impact. Its detailed elucidation of cellular mechanisms, combined with practical demonstrations of therapeutic benefit, sets a new standard for research at the intersection of regenerative medicine and ophthalmic disease.

In conclusion, the utilization of iPSC-derived ITGA6-positive cells to restore aqueous humor outflow represents a beacon of innovation in glaucoma treatment. This research not only expands our understanding of disease pathophysiology but also exemplifies the promise of regenerative strategies in conquering complex, chronic conditions that have long challenged the medical community.

Article References:
Feng, P., Yu, C., Zhang, X. et al. iPSC-derived ITGA6-positive cells restore aqueous humor outflow in glaucoma eyes. Nat Commun 16, 9441 (2025). https://doi.org/10.1038/s41467-025-65475-8

Age-related macular degeneration is a leading cause of vision loss globally, particularly among individuals over 60 years old. The disease affects nearly 200 million people worldwide, manifesting most aggressively in its neovascular or “wet” form. This condition is characterized by the proliferation of aberrant blood vessels in the retina, a process termed pathological neovascularization. These vessels are prone to leakage, leading to retinal edema and hemorrhage, gradually impairing central vision if untreated. Present therapies involve frequent intravitreal administration of anti-angiogenic agents such as VEGF inhibitors, a protocol that imposes a substantial treatment burden on patients.

The Institute of Science Tokyo’s novel approach circumvents the need for direct ocular injections. Instead, the vaccine is delivered intramuscularly, inducing a systemic immune response that targets the pathological drivers of abnormal blood vessel growth. This method not only simplifies administration but potentially enhances patient compliance by eliminating the discomfort and risk associated with intraocular injections. The vaccine induces the production of antibodies against leucine-rich alpha-2-glycoprotein 1 (LRG1), a molecule found to be elevated in AMD patients and implicated in promoting angiogenesis in the eye.

The research, led by Professor Satoshi Uchida and Visiting Professor Yasuo Yanagi, employed two distinct mouse models to assess therapeutic efficacy: one with laser-induced choroidal neovascularization (CNV) and another exhibiting spontaneous CNV development. Following two intramuscular injections spaced 14 days apart, both models exhibited robust antibody generation and significant suppression of abnormal vascular growth. Remarkably, reductions in vascular leakage and lesion size reached over 80% in the induced model and about 55% in the spontaneous model, with visible effects emerging within a week post-initial vaccination.

Mechanistically, the mRNA vaccine utilizes a platform that encodes the LRG1 protein, which instigates the body’s immune system to produce neutralizing antibodies. Unlike traditional vaccines targeting pathogens, this therapeutic vaccine targets a host protein involved in pathological angiogenesis. This strategy effectively disrupts the aberrant signaling pathways that fuel neovascularization in AMD, thereby protecting retinal integrity without impeding normal vascular functions.

Safety evaluations revealed the vaccine did not induce deleterious immune reactions or compromise physiological angiogenesis required for ocular health. Importantly, no adverse effects on adjacent retinal tissues or systemic toxicity were observed in treated animals. The therapeutic outcomes mirrored those seen with standard anti-VEGF therapies, yet the novel intervention holds the promise of reduced treatment frequency and enhanced patient tolerability.

The success of this mRNA vaccine builds upon the transformative potential demonstrated by mRNA vaccines throughout the COVID-19 pandemic. This platform allows rapid development and versatile targeting, ushering in a new era where chronic diseases such as AMD can be addressed through immunization strategies. The vaccine’s systemic administration route signifies a paradigm shift in ocular pharmacotherapy, offering hope for drastically improving quality of life for millions suffering from neovascular eye diseases.

Further research is warranted to evaluate the translational potential of this vaccine in clinical settings. Human trials will be critical to confirm efficacy, dosage optimization, and long-term safety. If successful, this innovation could render the painful, frequent eye injections obsolete and reshape the standard treatment landscape for AMD and related retinal disorders.

The findings were published in the esteemed journal Vaccine in August 2025, underscoring the rapidly expanding horizon of mRNA technology applications. Financial support was provided by the Japan Agency for Medical Research and Development, the Japan Science and Technology Agency, and the Institute of Science Tokyo itself. Patent interests are associated with lead researchers, reflecting the commercial and therapeutic potential of the vaccine.

As global populations age, the burden of vision loss due to AMD continues to rise, imposing significant social and economic costs. Therapeutic strategies that can offer durable, less invasive protection against disease progression are urgently needed. This innovative mRNA vaccine embodies a visionary approach, promising to enhance treatment adherence while delivering efficacious results.

In conclusion, the Institute of Science Tokyo’s mRNA vaccine represents a landmark advancement in neovascular eye disease therapy. By harnessing the precision of genetic immunotherapy, it not only curtails pathological blood vessel growth but does so with a delivery method far less taxing than current intraocular injections. This breakthrough has the potential to revolutionize the management of AMD worldwide and pave the way for similar approaches to other chronic conditions characterized by pathological angiogenesis.

Subject of Research: Animals

Article Title: mRNA vaccination mitigates pathological retinochoroidal neovascularization in animal models

News Publication Date: August 13, 2025

Web References: http://dx.doi.org/10.1016/j.vaccine.2025.127451

Image Credits: Institute of Science Tokyo

Keywords: Health and medicine, Clinical research, RNA, Genetic material, Vaccine development, Macular degeneration, Vision disorders, Amyloidosis, Diseases and disorders, Vaccine research